Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03952637 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis
A Phase 1 study of Lysosomal Diseases and Gangliosidosis, sponsored by National Human Genome Research Institute (NHGRI).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT03952637 is a Phase 1 study of Lysosomal Diseases and Gangliosidosis that is actively recruiting participants, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 54 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03952637, a Phase 1 study of Lysosomal Diseases and Gangliosidosis, is actively recruiting participants, sponsored by National Human Genome Research Institute (NHGRI).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: GM1 gangliosidosis is a disorder that destroys nerve cells. It is fatal. There is no treatment. People with GM1 are deficient in a certain enzyme. A gene therapy may help the body make this enzyme. This could improve GM1 symptoms. Objective: To test if a gene therapy helps Type I and Type II GM1 gangliosidosis symptoms. Eligibility: Type I subjects will be male and female \>= 6 months \<= 12 months of age at the time of full ICF signing. Type II subjects will be male and female \> 12 months old and \< 12 years old at the time of full ICF signing. Design: Participants will be screened with their medical history and a phone survey. Participants will stay at NIH for 8-10 weeks. Participants will have baseline tests: Blood, urine, and heart tests Hearing tests Ultrasound of abdomen EEG: Sticky patches on the participant s head will measure brain function. Lumbar puncture: A needle will be stuck into the participant s spine to remove fluid. MRI scans, bone x-rays, and bone scans: Participants will lie in a machine that takes pictures of the body IQ tests Neurology exams Central line placement Skin biopsy: A small piece of the participant s skin will be removed. Speech tests Participants will have an x-ray while swallowing food. Participants will take drugs by mouth and IV. This will get their immune system ready for therapy. Participants will get the gene therapy by IV. They may stay at NIH for a week to watch for side effects. Participants will have visits 3 and 6 months after treatment. Then visits will be every 6 months for 2 years. Then they will have a visit at 3 years. Visits will take 4-5 days. Participants will return to NIH once a year for 2 years for tests in an extension study....
Conditions Studied
Interventions
- DRUG Sirolimus
- DRUG Rituximab
- DRUG Methylprednisolone
- BIOLOGICAL AAV9-GLB1
- PROCEDURE Abdominal ultrasound
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2019-08-19 |
| Est. Completion | 2028-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03952637
The ClinicalTrials.gov registry entry for NCT03952637 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Human Genome Research Institute (NHGRI), which has 185 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lysosomal Diseases appearing as the primary indexed condition, and to 5 interventions - of which Sirolimus is the first listed.
NCT03952637 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03952637 about?
NCT03952637 is a clinical study titled "A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis". Background: GM1 gangliosidosis is a disorder that destroys nerve cells. It is fatal. There is no treatment. People with GM1 are deficient in a certain enzyme. A gene therapy may help the body make this enzyme. This could improve GM1 symptoms. Objective: To test if a gene therapy helps Type I and ...
What is the current status of trial NCT03952637?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2019-08-19. Estimated completion is 2028-01-01.
What conditions does trial NCT03952637 study?
This clinical trial studies the following conditions: Lysosomal Diseases, Gangliosidosis, GM1.
What interventions are being tested in trial NCT03952637?
The interventions under investigation include: Sirolimus (DRUG), Rituximab (DRUG), Methylprednisolone (DRUG), AAV9-GLB1 (BIOLOGICAL), Abdominal ultrasound (PROCEDURE).
Who is sponsoring clinical trial NCT03952637?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03952637 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.